Treatment pathways and clinical outcomes in Hodgkin lymphoma outside Europe and North America: results from the international, multicenter, retrospective, B-HOLISTIC study.


Journal

Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422

Informations de publication

Date de publication:
Dec 2022
Historique:
pubmed: 7 10 2022
medline: 26 1 2023
entrez: 6 10 2022
Statut: ppublish

Résumé

Information on Hodgkin lymphoma (HL) is mostly limited to Europe and North America. This real-world, retrospective study assessed treatment pathways and clinical outcomes in adults with stage IIB-IV classical HL receiving frontline treatment (

Identifiants

pubmed: 36200380
doi: 10.1080/10428194.2022.2126281
doi:

Substances chimiques

Cisplatin Q20Q21Q62J
Cytarabine 04079A1RDZ
Etoposide 6PLQ3CP4P3

Banques de données

ClinicalTrials.gov
['NCT03327571']

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3317-3330

Auteurs

Burhan Ferhanoglu (B)

Division of Hematology, Department of Internal Medicine, Koç University School of Medicine, Istanbul, Turkey.

Tae Min Kim (TM)

Department of Internal Medicine, Seoul National University Hospital, Seoul National University Cancer Research Institute, Seoul, South Korea.

Amado Karduss (A)

Bone Marrow Transplant Program, Instituto de Cancerologia, Clínica las Américas, Medellín, Colombia.

David Brittain (D)

Albert Alberts Stem Cell Transplant Center, Pretoria East Hospital, Pretoria, South Africa.

Gayane Tumyan (G)

Department of Chemotherapy of Hemoblastosis, Blokhin Russian Cancer Research Center, Moscow, Russia.

Mubarak Al-Mansour (M)

Adult Medical Oncology, Princess Noorah Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs-Western Region, Jeddah, The Kingdom of Saudi Arabia.
College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, The Kingdom of Saudi Arabia.

Marta Zerga (M)

Department of Hematology, Angel Roffo Institute, Buenos Aires, Argentina.

Yuqin Song (Y)

Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital, Beijing, China.

Silvia Rivas-Vera (S)

Department of Hematology, Instituto Nacional de Cancerologia Mexico, Mexico City, Mexico.

Yok Lam Kwong (YL)

Bone Marrow Transplant Unit, Queen Mary Hospital, Hong Kong, China.
Hematology Division, Medical Oncology and Bone Marrow Transplantation, Department of Medicine, University of Hong Kong, Hong Kong, China.

Soon Thye Lim (ST)

Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.

Su-Peng Yeh (SP)

Division of Hematology and Oncology, Department of Medicine, China Medical University Hospital, Taichung, Taiwan.

Arif Abdillah (A)

Takeda Pharmaceuticals International AG-Singapore Branch, Singapore, Singapore.

Zhongwen Huang (Z)

Takeda R&D Data Sciences Institute, Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.

Mehul Dalal (M)

Takeda R&D Data Sciences Institute, Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.

Hui Wan (H)

Takeda Pharmaceuticals International AG-Singapore Branch, Singapore, Singapore.

Mark Hertzberg (M)

Department of Clinical Haematology, Prince of Wales Hospital, Sydney, Australia.
University of New South Wales, Sydney, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH